[1] American Heart Association. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol,2018,38:e00-e00.
[2] Pose E, Trebicka J, Mookerjee RP, et al. Statins: Old drugs as new therapy for liver diseases? J Hepatol,2019,70:194-202.
[3] Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol,2012,56:374-380.
[4] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018, 67:328-357.
[5] Pollo-Flores P, Soldan M, Santos UC, et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig Liver Dis,2015,47:957-963.
[6] Bishnu S, Ahammed SM, Sarkar A, et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension. Eur J Gastroenterol Hepatol,2018,30:54-59.
[7] Abraldes JG, Villanueva C, Aracil C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology,2016,150:1160-1170, e3.
[8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志,2018, 21:170-176.
[9] Nascimbeni F, Aron-Wisnewsky J, Pais R, et al. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol,2016,3:e000075.
[10] Kamal S, Khan MA, Seth A,et al. Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis. Am J Gastroenterol,2017,112:1495-1505. |
